DiaSorin DIA.MI
DiaSorin is an Italian in-vitro diagnostics company that develops, produces, and sells laboratory kits and systems for clinical diagnostics, with a business model based on proprietary technology and a strong presence in the US market. DiaSorin shows solid financial health (score 6.77) with an operating margin of 22.38% and ROIC of 11.04%, although its valuation (P/E 29.03) and moderate growth (revenue +2.70%) limit its appeal. The return to growth in the U.S. is a positive factor, but governance risk in Italy and U.S. exposure add uncertainty.
Detailed metrics
Market and fundamental data as of the analysis date.
Full AI report
Generated automatically from the metrics, the macro context and the company's news.
DiaSorin is an Italian in-vitro diagnostics company that develops, produces, and sells laboratory kits and systems for clinical diagnostics, with a business model based on proprietary technology and a strong presence in the US market. DiaSorin shows solid financial health (score 6.77) with an operating margin of 22.38% and ROIC of 11.04%, although its valuation (P/E 29.03) and moderate growth (revenue +2.70%) limit its appeal. The return to growth in the U.S. is a positive factor, but governance risk in Italy and U.S. exposure add uncertainty.
Score by category
| Category | Score |
|---|---|
| Financial health | 6.8 |
| Quality / Moat | 5.8 |
| Valuation | 4.9 |
| Growth | 5.3 |
| Dividend | 6.3 |
| Momentum | 3.3 |
| Risk & Context | 4.9 |
OVERALL SCORE: 5.4/10
Context and risks
DiaSorin is domiciled in Italy, a country with elevated governance risk according to the assigned profile, justifying a jurisdictional risk penalty. Additionally, its strong exposure to the U.S. market (over 50% of revenue) makes it vulnerable to trade and regulatory tensions there, although no concrete event has materialized.
News considered in the analysis
- Diasorin SpA (DSRLF) (H1 2026) Earnings Call Highlights: Return to Growth, Strong U.S. ... — El retorno al crecimiento y la fortaleza en EE.UU. son hechos confirmados que mejoran las perspectivas de ingresos, aunque parte del rebote ya está en el precio.
- Is DiaSorin (BIT:DIA) Fairly Priced After Recent Share Price Rebound? — Artículo de análisis de valoración sin información nueva; no aporta datos concretos.
- Diasorin SpA (DSRLF) Full Year 2025 Earnings Call Highlights: Navigating Growth Amidst Global ... — Resultados anuales ya conocidos y ampliamente cubiertos; el mercado ya los ha descontado.
- Earnings To Watch: Diasorin SpA (MIL:DIA) Reports Q4 2025 Result — Aviso de publicación de resultados, sin información sustantiva.
- Diasorin SpA (FRA:34D) Q3 2025 Earnings Call Highlights: Navigating Growth Amidst Market Challenges — Resultados trimestrales pasados, ya descontados por el mercado.
Verdict: Hold; business quality is good, but valuation is not attractive and jurisdictional risk limits upside potential.
Main risk: The main risk is exposure to Italian governance and dependence on the U.S. market, where regulatory or trade tensions could impact revenues.
Other Healthcare companies
Neighbours in the sector ranking, to compare without going back to the index.
See all 1,000+ companies in the index →